Although SMEDDS has been reported to increase the bioavailability of many drugs by increasing water solubility, the increase in bioavailability of BCS IV compounds using SMEDDS is limited.
A likely explanation for this is promiscuous synergy in which one drug can affect the bioavailability of many other drugs, e.g., via effects on membrane composition.
In more recent years, better systemic bioavailability of many drugs has been achieved by oromucosal route.
These reactions control the concentration, speciation, behavior and bioavailability of many heavy-metal ions and organic pollutants in the environment.
The efflux transporters present in the intestine are known to reduce the bioavailability of many drugs.
Depending on efflux transporter interference with different compounds, bioavailability of compounds in a mixture can deviate from that of the same components when they are present alone.
The bioavailability of the compounds in these supplements, which will be affected by many things including the digestive process, will be much different in vivo than what the immune cells were exposed to in terms of an aqueous extract in these experiments.
It provides many advantages including capability of increasing the bioavailability of poorly soluble compounds, providing protection for sensitive active compounds, and facilitating controlled release of drugs [ 11, 12].
The oral bioavailability of lipophilic bioactive compounds such as many pharmaceuticals and nutraceuticals can be enhanced using triacylglycerol-based lipid nanoparticle delivery systems.
To explore the drug-likeness and bioavailability of the compounds in FFDS, we used SwissADME (http://www.swissadme.ch/ 63,64 as a tool to calculate the drug-likeness and bioavailability of each compound.
